Core Insights - Harrow is launching the Harrow Access for All (HAFA) program to enhance patient access to its ophthalmic medications, building on the success of the VEVYE Access for All (VAFA) initiative [1][2][4] Summary by Sections HAFA Program Overview - HAFA aims to provide a unified access point for Harrow's comprehensive ophthalmic portfolio, including branded, authorized generics, and compounded medications, set to launch in late 2025 [3][4] - The program is designed to improve affordability and streamline the prescribing process, ultimately supporting better patient outcomes and greater efficiency for physicians [3][4] Program Highlights - Eligible commercially insured patients may pay as little as $0, with out-of-pocket costs capped at $59 for all eligible patients, ensuring affordability regardless of coverage status [5] - HAFA will be implemented in three phases, with Phase 1 launching in Q4 2025, covering the majority of Harrow's specialty product portfolio [5] - Phase 2 is expected in the first half of 2026, expanding the portfolio of authorized generics, while Phase 3 in 2027 will extend across Harrow's full range of specialty, AGx, and compounded medicines [5] Technology and Efficiency - The HarrowAccess.com portal will streamline the prescribing process, allowing prescribers to manage prescriptions efficiently and reducing administrative burdens [10] - The platform will integrate with providers' EMR systems, ensuring automatic access to HAFA benefits for patients without additional steps [7][10] Commitment to Patient Access - The CEO of Harrow emphasized the company's commitment to reducing access barriers in ophthalmology, aiming to ensure that every patient can access sight-preserving medications without delay [4] - The program is seen as a significant step towards addressing the challenges of access and affordability in prescription medications, which have been longstanding issues in the industry [7]

Core Insights - Harrow has acquired exclusive U.S. commercial rights for BYQLOVI™, a new ophthalmic steroid approved by the FDA for post-operative inflammation and pain, marking a significant advancement in the eyecare pharmaceutical market [1][2] Company Overview - Harrow is a leading North American eyecare pharmaceutical company focused on innovative ophthalmic products, aiming to enhance patient access and outcomes [16] - Formosa Pharmaceuticals is a clinical stage biotechnology company specializing in ophthalmology and oncology, utilizing proprietary nanoparticle formulation technology to improve drug delivery [15] Product Details - BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05% is indicated for treating post-operative inflammation and pain following ocular surgery [5] - The product is expected to be available in the U.S. market in the fourth quarter of 2025 [1] Clinical Efficacy - Clinical studies show that 77% to 85% of patients reported no pain at Day 4 post-surgery, and 82% to 87% reported no pain at Day 8 post-surgery, indicating strong pain relief [3] - Inflammation clearance was also notable, with 33% and 30% of patients showing zero cell counts in the anterior chamber at Day 8 post-surgery [3] Safety Profile - Only 1.4% of patients experienced elevated intraocular pressure (IOP), significantly lower than other ophthalmic steroids, suggesting a favorable safety profile [4] - The dosing regimen is user-friendly, requiring only 1 drop twice daily for 14 days without a loading dose [4] Market Potential - The U.S. market for ophthalmic surgeries exceeds 7 million annually, presenting a substantial opportunity for BYQLOVI to capture market share in the multi-billion-dollar post-surgical care segment [2]